These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38316186)

  • 41. Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: post-dialysis versus intradialytic administration.
    Mason NA; Neudeck BL; Welage LS; Patel JA; Swartz RD
    Clin Nephrol; 2003 Aug; 60(2):96-104. PubMed ID: 12940611
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low-density lipoprotein apheresis decreases ferritin, transferrin and vitamin B12, which may cause anemia in serially treated patients.
    Bramlage CP; Armstrong VW; Zapf A; Bramlage P; Mueller GA; Koziolek MJ
    Ther Apher Dial; 2010 Apr; 14(2):136-42. PubMed ID: 20438534
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Subtherapeutic serum vancomycin concentrations during on-line hemodiafiltration.
    Sombolos KI; Fragidis SK; Bamichas GI; Hatsiou VN; Rizos AK; Natse TA; Fytili CI
    ASAIO J; 2011; 57(6):507-10. PubMed ID: 21946313
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low-density lipoprotein apheresis reduces platelet factor 4 on the surface of platelets: a possible protective mechanism against heparin-induced thrombocytopenia and thrombosis.
    Tanhehco YC; Rux AH; Sachais BS
    Transfusion; 2011 May; 51(5):1022-9. PubMed ID: 20977482
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An update on vancomycin dosing and monitoring practices in hemodialysis patients.
    Zhang M; Dresser L; Battistella M
    CANNT J; 2013; 23(4):25-7; quiz 28-9. PubMed ID: 24660521
    [No Abstract]   [Full Text] [Related]  

  • 46. Two Patients with Familial Hypercholesterolemia Who Were Successfully Weaned from Low-density Lipoprotein Apheresis after Treatment with Evolocumab.
    Tanaka A; Inaguma D; Watanabe Y; Ito E; Kamegai N; Shimogushi H; Shinjo H; Koike K; Otsuka Y; Takeda A
    Intern Med; 2017; 56(12):1531-1535. PubMed ID: 28626179
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of LDL-apheresis on the pharmacokinetics of the lipophilic antilipidemic agent probucol.
    Komura T; Takahara K; Sugano M; Fujinishi A; Tasaki H; Nakashima Y; Kuroiwa A
    Eur J Drug Metab Pharmacokinet; 1997; 22(3):201-6. PubMed ID: 9358199
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of selective LDL apheresis on serum chemerin levels in patients with hypercholesterolemia.
    Varga VE; Lőrincz H; Zsíros N; Fülöp P; Seres I; Paragh G; Balla J; Harangi M
    Lipids Health Dis; 2016 Oct; 15(1):182. PubMed ID: 27756331
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Relationship between platelet hyperactivation and dyslipoproteinemia in diabetic nephropathy].
    Tóth L; Szénási P; Varsányi-Nagy M; Szilvási I; Vörös P; Romics L; Kammerer L
    Orv Hetil; 1992 Apr; 133(17):1037-40. PubMed ID: 1579341
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influence of cellulose triacetate hemodialyzers on vancomycin pharmacokinetics.
    Welage LS; Mason NA; Hoffman EJ; Odeh RM; Dombrouski J; Patel JA; Swartz RD
    J Am Soc Nephrol; 1995 Oct; 6(4):1284-90. PubMed ID: 8589298
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Short- and long-term effects of LDL-apheresis on lipoprotein (a) serum levels.
    Ritter MM; Sühler K; Richter W; Schwandt P
    Clin Chim Acta; 1990 Dec; 195(1-2):9-15. PubMed ID: 2151209
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rationale and study design of a clinical trial to assess the effects of LDL apheresis on proteinuria in diabetic patients with severe proteinuria and dyslipidemia.
    Wada T; Muso E; Maruyama S; Hara A; Furuichi K; Yoshimura K; Miyazaki M; Sato E; Abe M; Shibagaki Y; Narita I; Yokoyama H; Mori N; Yuzawa Y; Matsubara T; Tsukamoto T; Wada J; Ito T; Masutani K; Tsuruya K; Fujimoto S; Tsuda A; Suzuki H; Kasuno K; Terada Y; Nakata T; Iino N; Kobayashi S
    Clin Exp Nephrol; 2018 Jun; 22(3):591-596. PubMed ID: 29080119
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low density lipoprotein-apheresis decreases oxidized low density lipoproteins and monocyte adhesion to endothelial cells.
    Cattin L; Petrucco A; Cazzolato G; Bon GB; Borelli V; Nardon E; Zabucchi G; Fonda M; Bordin P
    ASAIO J; 1997; 43(3):209-13. PubMed ID: 9152493
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lipoprotein composition in insulin-dependent diabetes mellitus with chronic renal failure: effect of kidney and pancreas transplantation.
    Hughes TA; Gaber AO; Amiri HS; Wang X; Elmer DS; Winsett RP; Hathaway DK; Hughes SM; Ghawji M
    Metabolism; 1994 Mar; 43(3):333-47. PubMed ID: 8139482
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Urea kinetics and dialysis treatment time predict vancomycin elimination during high-flux hemodialysis.
    Schaedeli F; Uehlinger DE
    Clin Pharmacol Ther; 1998 Jan; 63(1):26-38. PubMed ID: 9465839
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of low-density lipoprotein-apheresis on nephrotic syndrome due to membranous nephropathy in renal allograft: a case report.
    Ideura T; Hora K; Kaneko Y; Yamazaki T; Tokunaga S; Shigematsu H; Kiyosawa K
    Transplant Proc; 2000 Feb; 32(1):223-6. PubMed ID: 10701029
    [No Abstract]   [Full Text] [Related]  

  • 57. [Serum lipoprotein (a) levels during treatment with LDL apheresis for homozygous familial hypercholesterolemia].
    Lasunción MA; Teruel JL; Alvarez JJ; Gómez-Coronado D; Ortuño J; Herrera E
    Med Clin (Barc); 1992 Oct; 99(14):541-4. PubMed ID: 1434990
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increment of cerebral blood flow by LDL-apheresis in dialysis patients with arteriosclerosis obliterans: a pilot study.
    Nakajima F; Morimoto S; Yurugi T; Amari Y; Kasuno Y; Fukui M; Furumatsu Y; Kitamura T
    Int J Artif Organs; 2012 Nov; 35(11):981-5. PubMed ID: 23065872
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current status of low-density lipoprotein apheresis treatment for patients with peripheral artery disease and chronic kidney disease in Japanese clinical database.
    Watanabe Y; Tanaka A; Furuhashi K; Maruyama S
    Ther Apher Dial; 2023 Dec; 27(6):1000-1009. PubMed ID: 37587685
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low-density lipoprotein apheresis for the treatment of refractory hyperlipidemia.
    Vella A; Pineda AA; O'Brien T
    Mayo Clin Proc; 2001 Oct; 76(10):1039-46. PubMed ID: 11605688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.